No Data
No Data
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Express News | Quoin Pharmaceuticals Expands Netherton Syndrome Clinical Studies Internationally; First Site to Open in Saudi Arabia; Engages Experienced Local Clinical Research Organization; Plans for Additional Sites at Advanced Stage
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
Maxim Group Maintains Quoin Pharmaceuticals(QNRX.US) With Buy Rating, Maintains Target Price $4
No Data